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        Introduction 
  Skeletal muscle mass and fi  ber size is dynamically responsive 
to changes in workload that lead to increased muscle mass and 
strength. In contrast, muscle atrophy leads to signifi  cant weak-
ness in many infl  ammatory and infectious diseases, cancer, and 
human aging. Myopathies are muscle disorders characterized by 
atrophy of skeletal muscle. Proteins that regulate muscle hyper-
trophy are much sought after as therapeutic targets for reducing 
the debilitating effects of muscle atrophy and myopathies (  Patel 
and Muntoni, 2004  ). 
 Four-and-a-half LIM protein 1 (FHL1; also named SLIM1 
or KyoT1) belongs to the FHL protein family that comprises 
four and a half Lin-11, Isl-1, and Mec-3 (LIM) domains. FHL 
LIM domains mediate protein  –  protein interactions, scaffolding 
signaling proteins in the cytoplasm, and transcription factors in 
the nucleus (  McGrath et al., 2003  ,   2006  ;   Cottle et al., 2007  ). 
Three FHLs are expressed in skeletal muscle: FHL1, -2, and -3. 
There are no reports of FHL2 or 3 functioning to regulate skele-
tal muscle mass; rather, FHL2 regulates bone density (  Gunther 
et al., 2005  ), and in muscle cell lines, FHL3 inhibits differentia-
tion (  Cottle et al., 2007  ). FHL2 and 3 function as transcriptional 
corepressors and/or coactivators (  Johannessen et al., 2006  ; 
  Cottle et al., 2007  ); however, FHL1 transcriptional targets and 
function in skeletal muscle are largely uncharacterized. Several 
lines of evidence support an association between FHL1 expres-
sion and hypertrophy. FHL1 mRNA is up-regulated during em-
bryonic skeletal muscle development (  Loughna et al., 2000  ), 
increasing with postnatal skeletal muscle growth 10- to 15-fold, 
and also increasing two- to threefold in stretch-induced muscle 
hypertrophy ( Morgan et al., 1995 ;  Morgan and Madgwick, 1999 ; 
R
egulators of skeletal muscle mass are of interest, 
given the morbidity and mortality of muscle atro-
phy and myopathy. Four-and-a-half LIM protein 1 
(FHL1) is mutated in several human myopathies, including 
reducing-body myopathy (RBM). The normal function of 
FHL1 in muscle and how it causes myopathy remains un-
known. We ﬁ  nd that FHL1 transgenic expression in mouse 
skeletal muscle promotes hypertrophy and an oxidative 
ﬁ  ber-type switch, leading to increased whole-body strength 
and fatigue resistance. Additionally, FHL1 overexpression 
enhances myoblast fusion, resulting in hypertrophic myo-
tubes in C2C12 cells, (a phenotype rescued by calcineurin 
inhibition). In FHL1-RBM C2C12 cells, there are no hyper-
trophic myotubes. FHL1 binds with the calcineurin-
regulated transcription factor NFATc1 (nuclear factor of 
activated T cells, cytoplasmic, calcineurin-dependent 1), 
enhancing NFATc1 transcriptional activity. Mutant RBM-
FHL1 forms aggregate bodies in C2C12 cells, sequester-
ing NFATc1 and resulting in reduced NFAT nuclear 
translocation and transcriptional activity. NFATc1 also co-
localizes with mutant FHL1 to reducing bodies in RBM-
afﬂ  icted skeletal muscle. Therefore, via NFATc1 signaling 
regulation, FHL1 appears to modulate muscle mass and 
strength enhancement.
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mation (  McGrath et al., 2006  ). To investigate the role FHL1 
plays in myoblast fusion and differentiation, C2C12 skeletal myo-
blasts were transiently transfected with HA-FHL1 or HA-   gal 
control and induced to differentiate to myotubes. Over-
expression of FHL1 resulted in the formation of large  “ sac-like ”  
myotubes containing dense clusters of nuclei (  Fig. 1, C and D  , 
arrows), in contrast to the thin, elongated myotubes containing 
a linear arrangement of myonuclei observed in HA-   gal  control 
cells (  Fig. 1, A and B  ). 
[ID]FIG1[/ID]  Analysis of myotube diameters revealed 
a shift toward larger myotubes, with FHL1 overexpression re-
sulting in     20% of myotubes being   >  40   μ  m in diameter, com-
pared with only 5% of control myotubes (see   Fig. 7 B  ). 
  The large, sac-like myotube phenotype induced by FHL1 is 
reminiscent of myotube hypertrophy (  Palmer et al., 2001  ; 
  Rommel et al., 2001  ;   Pisconti et al., 2006  ;   Marshall et al., 2008  ), 
including hypertrophy caused by activation of the calcineurin  –
  NFAT pathway by insulin-like growth factor 1 (IGF-1;   Musar  ò   
et al., 1999 ;  Musar ò  and Rosenthal, 1999 ;  Semsarian et al., 1999a ). 
To determine if FHL1 promoted myotube hypertrophy via the 
calcineurin – NFAT  pathway,  HA-FHL1 – expressing  myoblasts 
were treated with the calcineurin inhibitor cyclosporine A (CsA) 
at the onset and throughout the course of differentiation (  Fig. 1, 
E and F  ). CsA inhibits the differentiation of primary muscle cul-
tures and some muscle cell lines ( Musar ò  et al., 1999 ;  Delling et al., 
2000  ;   Friday et al., 2000  ); however, differentiation of the C2C12 
myoblast cell line is totally resistant to CsA (  Palmer et al., 2001  ). 
Indeed, CsA did not impede differentiation of HA-   gal  control-
expressing myotubes (  Fig. 1 E  ). This allowed us to uniquely as-
sess whether FHL1-induced myotube hypertrophy was dependent 
on calcineurin  –  NFAT signaling, uncomplicated by the effects of 
CsA on myoblast differentiation by itself  .   Interestingly,  CsA  pre-
vented FHL1-induced hypertrophic myotube formation (  Fig. 1 F  ), 
which suggests that FHL1 may promote myotube hypertrophy 
via regulation of the calcineurin  –  NFAT pathway. 
  Skeletal muscle hypertrophy is characterized by enhanced 
transcription/translation leading to increased protein synthesis, 
predominantly of myofi  brillar proteins, which may be coupled 
with reduced protein breakdown ( Furmanczyk and Quinn, 2003 ; 
  Boonyarom and Inui, 2006  ). Concomitant with increased pro-
tein synthesis, and perhaps a feature of more advanced hyper-
trophy (  Sandri, 2008  ), is activation and fusion of quiescent 
myoblasts called satellite cells with each other or with existing 
myofibers, resulting in myonuclei addition (  Adams, 2006  ; 
  O  ’  Connor and Pavlath, 2007  ). We next evaluated whether 
FHL1-induced myotube hypertrophy was a consequence of en-
hanced myoblast fusion and/or differentiation and if this was 
accompanied by increased protein synthesis. Myoblasts stably 
expressing HA-FHL1 or HA-    gal control generated as de-
scribed previously (  McGrath et al., 2006  ) were induced to dif-
ferentiate for 0  –  96 h and stained with markers of myoblast 
differentiation, myogenin and sarcomeric myosin heavy chain 
(MHC;   Fig. 2 A  ;   Cottle et al., 2007  ) 
[ID]FIG2[/ID] . Differentiation was as-
sessed by scoring the percentage of myogenin-positive nuclei, 
which revealed a twofold increase in HA-FHL1  –  expressing 
cells, but only after 96 h differentiation (  Fig. 2 B  ). The differen-
tiation index represents the proportion of nuclei that are local-
ized within MHC-positive myotubes and is used as a measure of 
  Loughna et al., 2000  ). Conversely, FHL1 mRNA decreases dur-
ing disuse-induced muscle atrophy (  Loughna et al., 2000  ). 
However, whether FHL1 itself directly promotes skeletal mus-
cle hypertrophy or whether FHL1 mRNA increases as a conse-
quence of hypertrophy is unknown. 
  Recently, FHL1 mutations have been identifi  ed in three 
human myopathies, including an X-linked, recessive, adult-
onset scapuloperoneal myopathy called XMPMA, which presents 
with postural muscle atrophy and a bent spine, with pseudo-
hypertrophy of other muscles (  Windpassinger et al., 2008  ); an 
X-linked dominant scapuloperoneal syndrome associated with 
muscle atrophy but no pseudohypertrophy ( Quinzii et al., 2008 ); 
and third, the most severe myopathy, a sporadic or familial re-
ducing body myopathy (RBM;   Schessl et al., 2008  ). Clinical 
severity in RBM ranges from early childhood-onset muscle 
weakness followed rapidly by death caused by respiratory fail-
ure to adult-onset muscle weakness with slower but relentless 
progression (  Brooke and Neville, 1972  ;   Kiyomoto et al., 1995  ; 
  Figarella-Branger et al., 1999  ;   Liewluck et al., 2007  ). RBM 
muscle shows cytoplasmic inclusions (reducing bodies), which 
contain aggregates proposed to arise from the accumulation of 
misfolded proteins (  Liewluck et al., 2007  ). The molecular 
mechanisms by which FHL1 mutations contribute to RBM or 
other myopathies remain unknown. 
  Here, we have investigated the role FHL1 plays in regulat-
ing postnatal skeletal muscle growth by generating transgenic 
mice that ectopically express FHL1 in skeletal muscle. These 
mice exhibit skeletal muscle hypertrophy, with increased whole-
body strength. Regulation of calcineurin/nuclear factor of acti-
vated T cells (NFAT) signaling may benefit select types of 
muscular dystrophy (  Chakkalakal et al., 2004  ;   St-Pierre et al., 
2004  ;   Parsons et al., 2007  ). We identify NFATc1 as a transcrip-
tional target of FHL1. Wild-type FHL1, but not FHL1 mutants 
associated with RBM, enhanced NFATc1 transcriptional acti  v-
ity. RBM mutant FHL1 sequestered NFATc1 to reducing-body 
aggregates, leading to its decreased nuclear translocation in re-
sponse to calcineurin activation. Therefore, FHL1 functions to 
increase skeletal muscle mass, and its loss of function and/or 
misfolding in RBM may sequester and trap its transcriptional tar-
gets to reducing-body aggregates. These studies identify FHL1 
as a potential therapeutic target for increasing skeletal muscle 
mass in human myopathies. 
  Results 
  FHL1 promotes myoblast fusion and 
myotube hypertrophy 
  Differentiation of skeletal myoblasts (myogenesis) is defi  ned by 
an ordered series of events (  Abmayr et al., 2003  ). After induc-
tion of differentiation, myoblasts withdraw from the cell cycle, 
then elongate, align, and fuse to form primary multinucleated 
myotubes. A second wave of myoblast fusion results in further 
myonuclei addition to nascent myotubes, followed by the as-
sembly of myofi  brillar proteins into the costamere and sarco-
mere (  Sanger et al., 2002  ). We have previously demonstrated 
that FHL1 promotes myoblast elongation in Sol8 myoblast cell 
lines (  McGrath et al., 2003  ) and is important for sarcomere for-1035 FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY   • Cowling et al. 
blast fusion to form myotubes, and expression persists in adult 
muscle (  Cox et al., 1990  ) in the elongated postmitotic cells 
of the somites, as well as in adult mature myofi  bers, but not 
satellite cells (  Gunning et al., 1987  ;   Miniou et al., 1999  ;   Shen 
et al., 2003  ). FHL1 transgenic mice were generated and two 
lines were characterized. Transgenic HA-FHL1 expression was 
restricted to skeletal muscle, most prominent in fast-twitch en-
riched muscles including gastrocnemius ( Fig. 3, B and C , GAS), 
extensor digitorum longus (EDL), plantaris, extensor carpi 
ulnaris (ECU), and fl  exor digitorum profundus (FDP), which 
is consistent with HSA promoter activity (  Tinsley et al., 1996  ), 
with no expression in other tissues (  Fig. 3 D  ). FHL1 transgenic 
sarcomere structure appeared undisturbed, with normal 
    -actinin localization at the Z-line (Fig. S1, A and B, available 
at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1). 
HA-FHL1 colocalized with endogenous FHL1 at the I-band 
(  Fig. 3 E  ;   McGrath et al., 2006  ). 
  FHL1 transgenic gastrocnemius muscle exhibited a sig-
nifi  cant increase in the total fi  ber cross-sectional area (CSA) at 
both 6 (1.2-fold;   Fig. 4, A and B  ) and 12 weeks of age (not de-
p icted). 
[ID]FIG4[/ID]  Analysis of gastrocnemius fi  ber diameters revealed an 
increase in the frequency of larger fi   bers  ( ≥ 50   μ m)  in  trans-
genic mice (  Fig. 4 C  ). Myofi  brils from FHL1 transgenic mice 
were signifi  cantly wider (1.3-fold) than the wild type (Fig. S1 C; 
  Rosenblatt and Woods, 1992  ). Therefore, FHL1 induces skele-
tal muscle hypertrophy in vivo. Skeletal muscle hypertrophy 
can be accompanied by a fi  ber type conversion (  Dunn et al., 
1999 ),  identifi  ed by scoring MHC isoform expression. A 10% 
increase in oxidative type 2A, MHC-positive fi  bers was de-
tected in FHL1 transgenic FDP muscle, with a corresponding 
decrease in 2X fi  bers; however, this latter trend was not statisti-
cally signifi  cant (  Fig. 4 D  ). No difference was detected in the 
frequency of type 2B (  Fig. 4 D  ) or type 1 fi  bers in FHL1 trans-
genic FDP muscle (not depicted); however, the FDP is com-
posed of   <  1% of type 1 fi  bers. Therefore, FHL1 promotes 
skeletal muscle hypertrophy associated with a switch toward 
oxidative fi  ber type expression. 
myoblast differentiation (  Sabourin et al., 1999  ;   Erbay et al., 
2003  ). Normally, this does not exceed     50% (  Yoshida et al., 
1998  ). HA-FHL1 myotubes exhibited a similar differentiation 
index to HA-    gal myotubes up until 72 h, but then increased 
approximately twofold at 96 h (  Fig. 2 C  ). Myoblast fusion was 
scored as total nuclei per MHC-positive myotube (  Sabourin 
et al., 1999  ). After a 96-h differentiation, HA-FHL1 cell lines 
showed enhanced cell fusion (  Fig. 2 D  ). Therefore, FHL1 may 
promote myoblast fusion. We detected no changes in the levels 
or temporal appearance of the muscle regulatory factors MyoD, 
Myf5, or myogenin in FHL1-expressing cells during differenti-
ation (  Fig. 2 E  ). However, a fi  vefold increase in MHC expression 
was detected in FHL1-expressing cells at 48 h of differentiation 
(  Fig. 2, E and F  ). Expression of MHC is induced during the 
latter stages of myoblast differentiation (  Cole et al., 1993  ); 
however, accretion of this major myofi  brillar protein is also 
indicative of muscle anabolism and hypertrophy (  Furmanczyk 
and Quinn, 2003  ). Analysis of the protein/DNA ratios in FHL1-
expressing myotubes compared with controls revealed a two-
fold increase in protein synthesis relative to DNA, a feature of 
skeletal muscle hypertrophy (  Fig. 2 G  ;   De Arcangelis et al., 
2005  ). These studies reveal that FHL1 increases the fusion of 
myoblasts. The increased protein/DNA ratio coupled with evi-
dence of MHC accretion may be indicative of myotube hyper-
trophy. An imbalance in the nuclear/cytoplasmic ratio caused 
by hyperfusion may lead to an increase in protein translation, 
which increases the myotube cytoplasmic volume (  Adams, 
2006 ;   O ’ Connor  and  Pavlath,  2007 ). 
  FHL1 induces skeletal muscle hypertrophy 
and increased strength 
  We next investigated whether FHL1 expression in postmitotic 
myofi  bers induced skeletal muscle hypertrophy in vivo. The 
FHL1 cDNA was fused to an HA tag (HA-FHL1) and linked to 
the human skeletal muscle     -actin (HSA) promoter (  Fig. 3 A  ), 
which drives skeletal muscle  –  specifi  c expression (  Brennan and 
Hardeman, 1993  ). 
[ID]FIG3[/ID]  Skeletal     -actin is expressed only after myo-
  Figure 1.       FHL1 induces formation of hypertrophic 
myotubes, dependent upon calcineurin signaling.   C2C12 
myoblasts were transiently transfected with HA-    gal con-
trol (A, B, and E) or HA-FHL1 (C, D, and F), and left un-
treated (A  –  D) or treated with the calcineurin inhibitor CsA 
(E and F) before and during induction of differentiation in 
low serum media for 96 h. Transfected cells were detected 
using an HA antibody (green) and costained with propidium 
iodide (red) to identify nuclei. Cells were visualized using 
laser scanning confocal microscopy. Arrows indicate hyper-
trophic myotubes. Bars, 100   μ  m.     JCB • VOLUME 183 • NUMBER 6 • 2008  1036
  Figure 2.       FHL1 promotes enhanced myocyte fusion.   (A) C2C12 myoblasts stably expressing HA-    gal or HA-FHL1 were differentiated and costained with 
anti-MHC (MF20, green), myogenin antibodies (blue), and propidium iodide (red). Cells were imaged using confocal microscopy. Shown are representa-
tive images after 96 h of differentiation. Myoblast differentiation was quantiﬁ  ed from 0  –  96 h. Arrows indicate examples of transfected myotubes. Bar, 70   μ  m. 
(B) The percentage of total nuclei positive for myogenin. (C) The differentiation index, determined by scoring the proportion of total nuclei within MHC-
positive cells (myocytes and myotubes). (D) The fusion index, the mean number of nuclei per MHC-positive cell. Black and gray lines represent HA-    gal con-
trol and HA-FHL1  –  expressing C2C12 cells, respectively. Data represent the mean from three independent experiments (  n   = 3)   ±   SEM in which   ≥  100 cells 
were counted for each replicate. (*, P   <   0.05; **, P   <   0.01). (E) Lysates (25   μ  g) from differentiating C2C12 cells stably expressing HA-    gal or HA-FHL1 
were immunoblotted with MyoD, Myf5, myogenin, MHC, and     -tubulin antibodies (loading control). (F) MHC expression was analyzed by densitometry 
and quantiﬁ  ed relative to     -tubulin. Data represent the mean from three independent experiments   ±   SEM (  n   = 3; **, P   <   0.01). (G) The DNA/protein ratio 
was determined. Data represent the mean from four independent experiments   ±   SEM (  n   = 4; **, P   <   0.01).     1037 FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY   • Cowling et al. 
.org/cgi/content/full/jcb.200804077/DC1). The total number of 
fi  bers in the FDP and EDL muscles was not altered (unpub-
lished data). Therefore, the skeletal muscle hypertrophy ob-
served in FHL1 transgenic mice is caused by an increase in the 
muscle fi  ber size, rather than hyperplasia, or an increase in fre-
quency of naturally occurring larger (type 2B) fi  bers. 
 Analysis  specifi  cally of type 2B fi  ber diameters, which 
were expressed at equivalent frequencies in both FHL1 trans-
genic and wild-type mice (  Fig. 4 D  ), identifi  ed an increase in 
the frequency of larger (  ≥  50   μ  m) fi  bers, with a corresponding 
decrease in smaller (  ≤  30   μ  m) fi  bers in both the FDP (  Fig. 4, E 
and F  ) and EDL muscle (Fig. S2, available at http://www.jcb
  Figure 3.       Generation of FHL1 transgenic mice.   (A) The linearized transgene contains the 2.2-kb HSA promoter, fused in frame to the human FHL1 coding 
sequence with an N-terminal HA tag and a C-terminal bovine growth hormone polyA tail (BGHpA). FHL1-RBM mutants C132F and H123Y are indicated. 
(B) Skeletal muscle lysates were immunoblotted for HA-FHL1 or     -tubulin in wild-type (WT) or FHL1 transgenic (TG) muscle (GAS, gastrocnemius; EDL, 
extensor digitorum longus; SOL, soleus plantaris; PLA, plantaris; ECU, extensor carpi ulnaris; FDP, ﬂ  exor digitorum profundus). A lysate prepared from 
C2C12 cells transfected with HA-FHL1 was used as a positive control (+). (C) The relative expression of HA-FHL1 was determined by densitometry of HA-
immunoreactive polypeptides, standardized relative to     -tubulin loading. HA-FHL1 expression is represented as a fold difference, relative to GAS, arbitrarily 
deﬁ  ned as one. Graph depicts mean   ±   SEM (GAS, EDL, SOL, and PLA:   n   = 3 mice; ECU and FDP: ***, P   <   0.005;   n   = 1 mouse). (D) Tissue lysates from 
WT or TG mice were immunoblotted for HA-FHL1 using anti-HA antibodies or     -tubulin. Lysates prepared from C2C12 cells transfected with HA-FHL1 were 
used as a positive control (+). (E) Longitudinal gastrocnemius muscle sections from WT or FHL-TG mice were stained with anti-FHL1 (green) or anti-HA (red) 
antibodies and imaged by confocal microscopy, then images were further resolved by deconvolution. Bars, 5   μ  m.     JCB • VOLUME 183 • NUMBER 6 • 2008  1038
  Figure 4.       FHL1 transgenic mice exhibit skeletal muscle hypertrophy, increased strength, and fatigue resistance.   (A) Transverse gastrocnemius sections 
were stained with a dystrophin antibody and viewed by confocal microscopy. Higher-magniﬁ  cation images are shown in the insets, with one ﬁ  ber outlined. 
Bars, 50   μ  m. Images were analyzed for ﬁ  ber area (B) and diameter (C;   n   = 3  –  4 mice; *, P   <   0.05). GAS, gastrocnemius. (D) Transverse FDP sections 
were stained with MHC isoform-speciﬁ  c antibodies, and the percentage of 2A, 2X, and 2B ﬁ  bers was calculated. The bar graph displays the frequency 
of each ﬁ  ber type in wild-type (WT) versus transgenic (TG) mice (  n   = 3  –  5 mice; ***, P   <   0.005). (E) Transverse FDP sections were stained for 2B MHC 1039 FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY   • Cowling et al. 
  Typically, the nuclei in adult muscle fi  bers reside at the 
fi  ber periphery. Nuclei located at the center of the fi  ber refl  ect 
satellite cell fusion with existing myofi  bers. A 2.1-fold increase 
in Pax-7 (a satellite cell marker)-positive nuclei (  Fig. 4 G  ) and 
an increase in the number of centralized nuclei were detected in 
FHL1 transgenic mice at 6 and/or 12 wk, in both gastrocnemius 
(1.8-fold) and FDP (3.3-fold) muscles (  Fig. 4, H and I  ). Satellite 
cells may be activated in both compensatory hypertrophy and 
extreme hypertrophy. The FHL1 transgene was expressed using 
the HSA promoter, which is active in muscle fi  bers in the mouse 
but not in satellite cells (  Gunning et al., 1987  ;   Miniou et al., 
1999  ;   Shen et al., 2003  ). Therefore, the increase in satellite cells 
in FHL1 transgenic muscle must be caused by a stimulatory ef-
fect of FHL1 overexpression in myofi  bers. 
  Next, we determined whether FHL1-induced skeletal mus-
cle hypertrophy could enhance muscle strength. A standard 
whole-body strength test was performed, which measures over-
all strength of the limb and abdominal muscles ( Joya et al., 2004 ). 
12-wk-old mice were initially evaluated; however, all mice 
showed a 100% pass rate. Signifi  cantly, mature (12-mo old) 
FHL1 transgenic mice exhibited a 7.4-fold increase in whole-
body strength relative to wild-type mice (  Fig. 4 J  ), which indi-
cates that FHL1 expression can enhance skeletal muscle strength 
in mature mice. 
 The muscle contractile properties of the EDL (Table S1, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1) 
and soleus (not depicted) were examined but showed no differ-
ence between FHL1 transgenic versus wild-type mice for twitch 
or tetanic force when normalized to the CSA. Also, the rate of 
force production or relaxation was unaltered, perhaps because 
of the increased type 2A fi  bers (  Fig. 4 D  ), which are slow to 
relax. Therefore, the increased whole-body strength exhibited by 
transgenic mice is a consequence of muscle hypertrophy and 
not increased myosin power stroke. In addition, greater fatigue 
resistance was detected in EDL transgenic muscle (  Fig. 4 K  ), 
which exhibited skeletal muscle hypertrophy (Fig. S2). This 
may be caused by the increase in oxidative type 2A fi  bers ob-
served in FHL1 transgenic mice (  Fig. 4 D  ). In the soleus mus-
cle, no difference was detected (unpublished data). However, 
the soleus showed low HA-FHL1 expression (  Fig. 3, B and C  ) 
and did not exhibit hypertrophy (not depicted). Therefore, FHL1 
induces skeletal muscle hypertrophy, increased muscle strength, 
and decreased susceptibility to fatigue. 
  Wild-type FHL1 binds NFATc1, and FHL1 
RBM-associated mutants demonstrate 
reduced NFATc1 binding 
  The FHL proteins play critical roles as transcriptional coactiva-
tors or repressors (  Johannessen et al., 2006  ;   Cottle et al., 2007  ). 
Calcineurin signaling is implicated in regulating myopathy-
related muscle degeneration, positively in some myopathies 
and negatively in others (  Chakkalakal et al., 2004  ;   St-Pierre 
et al., 2004  ;   Parsons et al., 2007  ). Calcineurin is a calmodulin-
dependent, calcium-activated protein phosphatase. Once 
activated, calcineurin dephosphorylates cytosolic NFAT tran-
scription factors, exposing a nuclear localization sequence 
and thereby promoting their nuclear translocation and tran-
scriptional events. NFATc1-c3 and NFAT5 are expressed in 
skeletal muscle (  Abbott et al., 1998  ;   O  ’  Connor et al., 2007  ). 
NFATc1 promotes skeletal muscle hypertrophy and oxidative 
myofi  ber-type identity (  Chin et al., 1998  ;   Semsarian et al., 
1999b ),  NFATc2  governs  myofi  ber number (  Horsley et al., 
2001  ), and NFATc3 regulates primary myotube formation 
during myogenesis (  Kegley et al., 2001  ). NFAT5 is a constitu-
tively nuclear, calcineurin-independent transcription factor, 
which regulates skeletal muscle cell migration and differentia-
tion (  O  ’  Connor et al., 2007  ). As FHL1 promoted hypertrophy 
and fi   ber type switching in vivo, which is reminiscent of 
NFATc1 function, we evaluated whether FHL1 interacted with 
NFATc1. GST-FHL1 bound His-NFATc1 in purifi  ed compo-
nent binding studies (  Fig. 5 A  ). 
[ID]FIG5[/ID]  In control studies, GST  –  GATA-2 
complexed with His-NFATc1 as described previously (  Musar  ò   
et al., 1999  ). Also, GST-FHL1, but not GST-coupled glutathione-
Sepharose, incubated with skeletal muscle lysate pulled 
down an     100-kD polypeptide that corresponds to endoge-
nous NFATc1 (  Fig. 5 B  ). We next asked whether FHL1-RBM 
mutants could also complex with NFATc1. C2C12 myoblasts 
were cotransfected with myc-NFATc1 and HA-FHL1 (wild 
type), HA-FHL1 
C132F , or HA-FHL1 
H123Y . HA-FHL1 was detected 
in myc-NFATc1 immunoprecipitates (  Fig. 5 C  ). In contrast, 
binding of RBM-FHL1 mutants to myc-NFATc1, although ev-
ident (  Fig. 5 C  ), was reduced by     80% (  Fig. 5 D  ). Mutant 
FHL1 is sequestered to reducing body aggregates in the skele-
tal muscle of RBM-affected individuals (  Schessl et al., 2008  ). 
Therefore, the RBM mutant FHL1  –  NFATc1 complex may be 
less accessible for immunoprecipitation because of its seques-
tration in reducing body aggregates. To investigate this possi-
bility, we examined the effect of wild-type or RBM mutant 
FHL1 on the subcellular localization of NFATc1; the latter has 
been found to localize to the myotube cytosol, and in response 
to calcineurin activation, in some but not all nuclei (  Abbott 
et al., 1998  ). In differentiated C2C12 cells, wild-type HA-
FHL1 and myc-NFATc1 colocalized in the cytosol (  Fig. 6 A  ). 
[ID]FIG6[/ID]  
FHL1 
C132F   and FHL1 
H123Y   localized diffusely in the cytosol but 
also in perinuclear cytoplasmic aggregates (  Fig. 6 A  , white 
arrowheads), which stained with the reducing body marker 
menadione  –  nitro blue tetrazolium chloride (NBT) in the ab-
sence of substrate (  Fig. 6 A  , black arrowheads), consistent with 
ﬁ  bers; one ﬁ  ber is outlined per image. Bars, 40   μ  m. (F) The diameters of FDP-2B ﬁ  bers from WT versus TG mice are shown (  n   = 3  –  4 mice; *, P   <   0.05). 
(G) The frequency of Pax-7  –  positive nuclei in the gastrocnemius was scored, relative to total nuclei. The bar graph represents the frequency of Pax-7  –  positive 
nuclei for WT and TG mice (  n   = 3  –  5 mice; **, P   <   0.01). (H) Transverse FDP sections were hematoxylin and eosin stained. Arrows indicate centralized 
nuclei. Bars, 40   μ  m. (I) The frequency of centralized nuclei were scored, relative to total myoﬁ  ber nuclei, in transverse gastrocnemius and FDP sections 
(  n   = 4  –  6 mice; *, P   <   0.05; ***, P   <   0.001). (J) A whole animal strength test measured overall limb and abdominal strength as a percentage pass rate 
over 15 trials for WT versus TG 12-mo-old mice (  n   = 4  –  8; **, P   <   0.01). All graphs represent mean   ±   SEM; WT, white; TG, gray. (K) Muscle fatigability 
was assessed as a drop in force with repeated tetanic contractions in EDL muscles from WT (black) versus TG (red) mice, expressed as a percentage of 
initial contraction over time, mean   ±   SEM (  n   = 7, P   <   0.02).     
 JCB • VOLUME 183 • NUMBER 6 • 2008  1040
(  Fig. 6, C and D  ). In contrast, NFATc1 nuclear localization 
was signifi  cantly reduced by HA-FHL1 
C132F  or HA-FHL1 
H123Y  co-
expression, revealing that RBM-FHL1 mutants may sequester 
NFATc1 to reducing bodies and therefore reduce NFATc1 
activity in the nucleus. 
  Wild-type FHL1, but not RBM-associated 
FHL1 mutants, coactivate NFATc1-
mediated transcription 
  FHL1 mutations have been identifi  ed in patients with RBM that 
occur in critical residues within the second LIM domain (C132F 
or H123Y) and have been predicted to disrupt folding of the 
LIM domain, and, therefore, impair protein binding (  Fig. 3 A  ; 
reducing-body aggregates in RBM skeletal muscle (  Schessl 
et al., 2008  ). Interestingly, NFATc1, when coexpressed with 
HA-FHL1 
C132F   or  HA-FHL1 
H123Y   but not wild-type FHL1, also 
localized to reducing body aggregates (  Fig. 6 A  , insets). We ob-
tained muscle biopsies from individuals with RBM and ex-
amined NFATc1 localization, revealing its reducing body 
aggregate colocalization with FHL1 (  Fig. 6 B  , arrowheads). 
We also determined the affect of FHL1-RBM mutants on 
NFATc1 nuclear translocation in response to the Ca 
2+   iono-
phore, ionomycin, which activates calcineurin signaling (  Abbott 
et al., 1998  ). NFATc1 nuclear translocation was detected in 
35% of myotube nuclei scored after ionomycin pretreatment, 
and this localization was not affected by FHL1 coexpression 
  Figure 5.       FHL1 forms a complex with NFATc1.   (A) GST-FHL1, GST-GATA-2, or GST and His-NFATc1 or His were coexpressed as indicated in   E. coli  . GST 
proteins and associated proteins were bound to glutathione-Sepharose. Western blots are representative of three experiments. Arrows indicate GST- and 
His-tagged proteins. The His tag alone did not copurify with GST-FHL1 (not depicted). (B) GST-FHL1 or GST coupled to glutathione-Sepharose was incubated 
with skeletal muscle lysates from wild-type FVB/n mice and immunoblotted for endogenous NFATc1, GST, or GST-FHL1 as indicated. Results shown are 
representative of four similar experiments. (C) Coimmunoprecipitation of HA-FHL1 and myc-NFATc1 in C2C12 cells. C2C12 cells were transfected with the 
indicated constructs and immunoprecipitated with a myc antibody, then immunoblotted with an HA antibody (top). Immunoprecipitation of myc-NFATc1 was 
conﬁ  rmed by immunoblotting with myc antibody (middle). Lysates were immunoblotted with an HA antibody to conﬁ  rm equal expression of FHL1 constructs 
(bottom). Immunoblots are representative of three experiments. (D) Densitometric quantiﬁ  cation of HA-FHL1 wild-type or C132F/H123Y mutants, relative to 
immunoprecipitated myc-NFAT. The bar graph represents the mean   ±   SEM (  n   = 3 experiments; **, P   <   0.01).     1041 FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY   • Cowling et al. 
sis confi  rmed equal expression of wild-type and mutant FHL1 
(unpublished data). Therefore, FHL1, but not mutant FHL1 
associated with severe RBM, induces hypertrophic myotubes, a 
phenotype that we have demonstrated is dependent on calcineu-
rin signaling. 
  We next investigated whether FHL1 binding to NFATc1 
regulates NFATc1-dependent transcription. NFATc1 binds the 
IL-2 promoter, an NFAT-responsive gene in striated muscle 
(  Ichida and Finkel, 2001  ). For C2C12 myoblasts grown in serum 
(growth conditions), the basal IL-2 reporter activity in vector-
control cells was increased approximately threefold by coex-
pression of NFATc1, and further transactivated approximately 
ninefold by FHL1 (  Fig. 7 C  ). FHL1 
C132F   and FHL1 
H123Y   exhib-
ited reduced ability to transactivate NFAT-mediated IL-2 pro-
moter reporter activity. Similarly, after myoblast differentiation, 
wild-type FHL1 but not RBM-FHL mutants transactivated 
NFATc1 reporter activity ( Fig. 7 D ). To determine if this transcrip-
tional activation occurred in vivo, we examined for expression 
  Schessl et al., 2008  ). To examine the functional consequence of 
these mutations, C2C12 myoblasts were transiently transfected 
with HA-FHL1 
C132F   or HA-FHL1 
H123Y  , then induced to differen-
tiate, stained with an anti-HA antibody, and imaged using con-
focal microscopy (  Fig. 7 A  ). 
[ID]FIG7[/ID]  In control studies, myoblasts were 
transiently transfected with wild-type HA-FHL1 (HA-FHL1-WT; 
  Fig. 7 A  ). As described earlier (  Fig. 1  ), overexpression of wild-
type FHL1 induced the expression of large hypertrophic myo-
tubes. Interestingly, FHL1 
C132F   did not induce formation of 
hypertrophic myotubes (  Fig. 7 A  ), which suggests loss of FHL1 
function. In addition, C2C12 myotubes expressing FHL1 
C132F  
exhibited an approximately twofold increase in the frequency 
of smaller diameter (  ≤  20   μ  m) myotubes (  Fig. 7 B  ), which is 
reminiscent of the cell culture equivalent of muscle atrophy 
(  Stevenson et al., 2005  ). Expression of FHL1 
H123Y  , a mutation 
associated with a milder clinical phenotype, also induced hyper-
trophic myotubes; however, the majority of cells differentiated 
normally ( Fig. 7, A and B ). In control studies, immunoblot analy-
  Figure 6.       RBM-FHL1 mutations alter localization of NFATc1.   (A) C2C12 myoblasts were cotransfected with HA-FHL1 wild-type (top), HA-FHL1 
C132F   (middle), 
or HA-FHL1 
H123Y   (bottom), and myc-NFATc1, then differentiated for 72 h. Myotubes were ﬁ  xed and costained with HA (green) and myc (red) antibodies, 
costained with menadione-NBT, and imaged by ﬂ  uorescence microscopy. White arrowheads indicate perinuclear aggregates colocalizing with the reducing-
body marker menadione-NBT in the absence of substrate (black arrowheads). Yellow arrowheads reveal the region shown in the high-magniﬁ  cation 
images showing colocalization between FHL1, NFATc1, and menadione-NBT in the insets. (B) Transverse skeletal muscle sections were prepared from 
human RBM muscle biopsies, with FHL 
C132F   (top) or FHL1 
H123Y   (bottom) mutations. Sections were stained with antibodies recognizing FHL1 (green) and 
NFATc1 (red), then costained with DAPI (nuclei). Arrowheads identify reducing bodies. (C) Vector control, FHL1 wild-type (FHL1-WT), or indicated FHL1 
RBM mutants were cotransfected with myc-NFATc1 into C2C12 myoblasts. Myoblasts were differentiated for 72 h, then ionomycin-stimulated for 30 min, 
and costained with anti-myc (NFATc1, glow-over images are shown) and anti-HA (to identify cotransfected cells, not depicted here). White arrows identify 
NFATc1 nuclear staining, yellow arrows indicate NFATc1-negative nuclei. High-magniﬁ  cation images are shown in the insets. (D) The percentage of trans-
fected cells containing nuclear NFATc1 was scored after ionomycin stimulation. The bar graph equals mean   ±   SEM (  n   = 4 experiments; *, P   <   0.05). Bars: 
(A and B) 20   μ  m; (C) 50   μ  m.     JCB • VOLUME 183 • NUMBER 6 • 2008  1042
  Figure 7.       FHL1 regulates the transcriptional activity of NFATc1 and expression of the calcineurin-responsive gene GATA-2.   (A) C2C12 myoblasts were tran-
siently transfected with HA-tagged wild-type (WT) FHL1, FHL1 
C132F  , or FHL1 
H123Y   and allowed to differentiate for 72 h, then costained with anti-HA antibody 
(green) and To-Pro-3 (blue) to detect nuclei. Cells were imaged using confocal microscopy. Arrows indicate hypertrophic myotubes. Bars, 100   μ  m. (B) Maxi-
mum myotube diameter was measured in myotubes transiently transfected with HA-tagged wild-type (WT) FHL1, FHL1 
C132F  , FHL1 
H123Y  , or HA-    gal control, 
then differentiated for 96 h and stained as described in Materials and methods. The bar graph represents the mean frequency of myotubes with diameters of 1043 FHL1 IN MUSCLE HYPERTROPHY AND MYOPATHY   • Cowling et al. 
of a calcineurin-responsive gene, GATA-2 ( Musar ò  et al., 1999 ), 
in transgenic muscle. Although not normally expressed in skel-
etal muscle, GATA-2 expression is induced in hypertrophic 
skeletal muscle, where, despite being a transcription factor, it 
localizes to the sarcolemma (  Paul and Rosenthal, 2002  ). Signif-
icantly, increased GATA-2 was detected in the gastrocnemius of 
FHL1 transgenic mice (  Fig. 7 E, F  ). Furthermore, in FHL1 
transgenic mice, increased GATA-2 was detected at the sarco-
lemma (  Fig. 7 G  ). 
  To verify that FHL1 regulates NFATc1 transcriptional ac-
tivity, the IL-2 promoter luciferase assay was repeated in C2C12 
cells under conditions of siRNA-mediated FHL1 knockdown, 
as described previously (  McGrath et al., 2006  ). Under growth 
conditions, FHL1 knockdown reduced NFATc1-dependent gene 
transcription     1.8-fold relative to the siRNA scrambled (con-
trol) sequence (  Fig. 7 H  ) and threefold under differentiation con-
ditions (  Fig. 7 I  ). FHL1 immunoblot analysis confi  rmed FHL1 
protein knockdown under growth and differentiation condi-
tions (Fig. S3, available at http://www.jcb.org/cgi/content/full/
jcb.200804077/DC1). Therefore, FHL1 is required for effi  cient 
NFATc1-mediated transcriptional activity. 
  Discussion 
  FHL1 has recently been identifi  ed as the gene mutated in sev-
eral familial and sporadic human myopathies (  Quinzii et al., 
2008  ;   Schessl et al., 2008  ;   Windpassinger et al., 2008  ). How-
ever, the normal function of FHL1 in skeletal muscle and its 
molecular targets are largely uncharacterized. The discovery 
that FHL1 expression increases muscle fi  ber size and oxida-
tive slow fi  ber type expression, leading to increased muscle 
strength and endurance, identifi  es it as a regulator of skeletal 
muscle mass. FHL1 complexes with NFATc1, thereby enhanc-
ing its transcriptional activity. In contrast, mutant FHL1 pro-
teins that cause RBM sequestered NFATc1 to reducing body 
aggregates, resulting in decreased NFATc1 nuclear transloca-
tion and transcriptional activity. Collectively, the data pre-
sented here provide evidence for a role for FHL1 in regulating 
skeletal muscle mass via regulation of NFATc1 transcriptional 
activity (  Fig. 8  ). 
[ID]FIG8[/ID]  
  FHL1 transgenic mice exhibited skeletal muscle hypertro-
phy rather than hyperplasia, showing a     20% increase in fi  ber 
size but no change in fi  ber number. However, this was insuffi  -
cient to increase overall muscle weight relative to body weight 
(unpublished data). The increase in muscle fi  ber size in FHL1 
transgenic mice induced an approximately sevenfold increase in 
whole-body strength, with a persistent increase in muscle func-
tion, as enhanced muscle strength was observed in 12-mo-old 
mice. FHL1 induced a fi  ber type switch and increased the fre-
quency of centralized myonuclei, which is consistent with 
hypertrophy. Overexpression of FHL1 also induced myotube 
hypertrophy in cultured C2C12 cells, as shown by increased 
myotube size, MHC accretion, and an increased protein/DNA 
ratio. These results, combined with the severe myopathy ob-
served in individuals with FHL1 mutations, highlight the ability 
of FHL1 to regulate muscle mass. 
  Growth factors and increased muscle stretching or loading 
stimulate satellite cell proliferation and fusion with existing 
myofi  bers, leading to both increased myofi  ber size and central-
ization of myonuclei (  Barton-Davis et al., 1999  ;   Paul and 
Rosenthal, 2002  ). Hypertrophy is a multistep process and can 
occur because of expansion of the myofi  ber that is driven from 
within the fi  ber through maximized transcription and transla-
tion, resulting in increased protein synthesis. Enhanced myo-
blast differentiation and fusion also contribute to hypertrophy 
(  Sandri, 2008  ). FHL1 may facilitate myofi  ber hypertrophy via 
enhanced myoblast fusion, as shown in C2C12 myoblasts and 
also through a mechanism within the fi  ber, as shown by the 
FHL1 transgenic muscle, in which the HSA promoter sequences 
   
  Figure 8.       FHL1 regulates NFAT-mediated signaling in skeletal muscle.   
Wild-type FHL1 complexes with NFATc1 to increase its transcriptional 
activity, promoting skeletal muscle hypertrophy and oxidative ﬁ  ber type 
expression. FHL1-RBM mutations sequester NFATc1 into reducing body ag-
gregates, resulting in its reduced nuclear translocation and reduced activa-
tion of gene transcription.     
0  –  20   μ  m,   >  20  –  40   μ  m, and   >  40   μ  m,   ±  SEM (  n     >   300 myotubes from three experiments;   n   = 3; *, P   <   0.05). (C) C2C12 myoblasts were cotransfected with 
various combinations of expression vectors as indicated, and with NFATc1-dependent (  pGL2-IL-2  ) and Renilla luciferase reporters. Transfected myoblasts 
were maintained in growth media for 48 h and assayed for luciferase activity. Gal4DBD activity is represented by white bars and Gal4DBD-NFATc1 by 
gray bars. Error bars represent   ±   SEM (n   ≥   5 experiments; *, P   <   0.05). (D) Transfected myoblasts were differentiated for 48 h and assayed for luciferase 
activity (48 h;   n   = 4 experiments). (E) Gastrocnemius (GAS) lysates from wild-type (WT) or HA-FHL1 transgenic (TG) mice were immunoblotted for GATA-2 
or     -tubulin (loading control). (F) GATA-2 protein expression levels in WT (white) versus TG (gray) gastrocnemius muscle was quantiﬁ  ed using densitometry 
and standardized to the loading control. The bar graph represents the mean   ±   SEM (  n   = 5 mice per genotype; *, P   <   0.05). (G) Transverse gastrocnemius 
muscle sections were costained with anti  –  GATA-2 (green), anti-vinculin (red; sarcolemma) antibodies, and To-Pro-3 iodide nuclear stain (blue), then imaged 
by confocal microscopy. Images were taken at the same intensity. Bars, 40   μ  m. (H) C2C12 cells were cotransfected with various combinations of expression 
vectors for Gal4DBD (white) or Gal4DBD-NFATc1 (gray) and either scrambled (control) or FHL1 siRNA oligonucleotides, as indicated, with NFATc1-dependent 
(  pGL2-IL-2  ) and Renilla luciferase reporters. Assays were performed under growth conditions. Error bars represent   ±  SEM (  n   = 5 experiments; *, P   <   0.05). 
(I) Luciferase assays performed in H were repeated under differentiation (48 h) conditions (  n   = 3 experiments; *, P   <   0.05).     
 JCB • VOLUME 183 • NUMBER 6 • 2008  1044
RBM may arise from the accumulation of misfolded/unfolded 
FHL1 protein, (  Meredith, 2005  ;   Liewluck et al., 2007  ). Mutant 
FHL1 may bind NFATc1 with less affi  nity, as suggested by 
coimmunoprecipitation. Alternatively, the FHL1 – NFATc1 com-
plex is cosequestered to insoluble reducing body aggregates, 
making it less accessible for immunoprecipitation. 
 The  FHL1 
C132F   or FHL1 
H123Y   mutations that cause RBM 
affect conserved, zinc-coordinating residues located in the 
second LIM domain. Two other myopathies in which FHL1 is 
mutated have been described. In one family, a W122S missense 
mutation was found in the second LIM domain, resulting in 
adult-onset X-linked dominant scapuloperoneal myopathy 
(  Quinzii et al., 2008  ). Reducing bodies were not described in 
this paper. A third study describes a C224W missense muta-
tion in the FHL1 fourth LIM domain and an isoleucine inser-
tion between residue 127 and 128 in the second LIM domain. 
These mutations are both associated with a clinical presenta-
tion comprising adult-onset X-linked recessive disorder with 
hypertrophy of type 2 fi  bers, leading to pseudo-athleticism 
with atrophy of type 1 fi  bers, associated with postural atrophy 
and bent spine (XMPMA;   Windpassinger et al., 2008  ). Whether 
these mutations also cause alteration in calcineurin  –  NFAT 
signaling is the subject of ongoing studies. These studies col-
lectively describe seven distinct FHL1 mutations in sporadic 
and inherited myopathies, which lead to distinct phenotypes. 
  The calcineurin  –  NFAT pathway promotes muscle re-
generation in some human myopathies (  Sakuma et al., 2003  ). 
Calcineurin stimulation can ameliorate dystrophic pathology 
and myofi  ber atrophy, whereas a blockade of calcineurin sig-
naling severely compromises muscle regeneration in   mdx  
dystrophic mice (  Chakkalakal et al., 2004  ). Genetic disruption 
of calcineurin improves the muscle pathology in    -sarcoglycan –
  null mice, a mouse model of limb girdle muscular dystrophy-
2F (  Parsons et al., 2007  ), which implies a functional link 
between calcineurin  –  NFAT signaling and dystrophy/myopa-
thy. We predict in RBM that the cosequestration of NFATc1 
with mutant FHL1 to reducing bodies leads to loss of FHL1 
function in enhancing muscle mass and impairs calcineurin  –
 NFATc1  signaling. 
  In summary, we have identifi  ed FHL1 as a novel regula-
tor of skeletal mass. FHL1 binds and regulates NFATc1 tran-
scriptional activity, and this signaling complex is mislocalized 
into cytoplasmic aggregates in RBM. FHL1 may therefore 
represent a novel therapeutic target for increasing skeletal 
muscle mass in myopathies and conditions associated with 
muscle atrophy. 
  Materials and methods 
  Constructs 
  pCGN-FHL1 (human cDNA, GenBank/EMBL/DDBJ accession no. 
  NM_001449  ), pGEX-5   ×   1-FHL1, and pCGN-    gal (vector control) have been 
de  scribed previously (  McGrath et al., 2003  ,   2006  ). pCMX and G5E1b-LUC 
vectors were gifts from R. Schule, (University of Freiburg, Freiburg, Germany). 
Mouse NFATc1 cDNA (GenBank/EMBL/DDBJ accession no.   NM_016791  ) 
was PCR ampliﬁ  ed from GFP-RV-DV-NFATc1 (plasmid 11101; Addgene; Table 
S2, available at http://www.jcb.org/cgi/content/full/jcb.200804077/DC1; 
  Monticelli and Rao, 2002  ), and cloned into pCMX; pET-30a(+) (Novagen) and 
pEFBOS (provided by T. Wilson, the Walter and Eliza Hall Institute of Medical 
directed FHL1 expression in postmitotic myofi  bers. The ob-
served increase in the frequency of centralized myonuclei in 
FHL1 transgenic skeletal muscle is consistent with enhanced 
fusion of activated satellite cells. 
  After dephosphorylation by calcineurin, NFATs translo-
cate to the nucleus and activate or repress target genes (  Horsley 
and Pavlath, 2002  ). Skeletal muscle electrical activity also 
promotes NFATc1 nuclear entry via calcineurin activation; 
however, NFATc1 can also shuttle in and out of the nucleus in 
the absence of calcineurin activation (  Shen et al., 2006  ). Cal-
cineurin signaling is proposed to regulate skeletal muscle fi  ber 
type switching (  Chin et al., 1998  ;   Naya et al., 2000  ). Early stud-
ies suggested calcineurin could induce skeletal muscle hyper-
trophy (  Dunn et al., 1999  ;   Semsarian et al., 1999b  ). However, 
transgenic mice expressing constitutively active calcineurin 
A     (CnA   ) in skeletal muscle do not exhibit hypertrophy 
(  Naya et al., 2000  ), and gene-targeted deletion of specifi  c 
calcineurin-isoforms (CnA     or  CnA   ) does not lead to changes 
in myofi  ber diameter (  Parsons et al., 2004  ). Calcineurin inhi-
bition with high doses of CsA, which inhibits activation of 
most calcineurin isoforms, reduces overload-induced skeletal 
muscle hypertrophy. This suggests that global inhibition of 
all calcineurin activity may inhibit hypertrophy (  Dunn et al., 
1999  ). The calcineurin  –  NFAT pathway also promotes myoblast 
fusion to myotubes by enhancing IL-4 transcription (  Fornaro 
et al., 2006  ). 
  We propose that FHL1 increases in muscle mass are a 
consequence of enhancing NFAT transcriptional activity. FHL1 
promotes hyperfusion of C2C12 myoblasts, reversed by inhibi-
tion of the calcineurin – NFAT pathway. FHL1 transgenic muscle 
showed a muscle fi  ber type switch, which is consistent with 
calcineurin  –  NFAT activation, and increased expression of the 
calcineurin-responsive gene, GATA-2. NFATc2 is critical for 
sec ondary  myogenesis,  specifi  cally the fusion of myoblasts with 
existing myotubes/myofi  bers (  Horsley et al., 2001  ). NFATc2 
knockout mice exhibit reduced muscle mass, a decrease in myo-
fi  ber CSA, and reduced myonuclei number. Myoblast fusion 
occurs through an ordered series of events, which includes myo-
blast elongation, alignment, and fusion (  Abmayr et al., 2003  ). 
We found that FHL1 promotes the hyper-elongation of myo-
blasts in an integrin-dependent manner (  McGrath et al., 2003  ). 
Myoblast elongation is a critical step before myoblast fusion 
(  Straube and Merdes, 2007  ;   Fortier et al., 2008  ). The ability of 
FHL1 to promote myoblast elongation may contribute to the 
observed hyperfusion effect. 
  RBM occurs because of mutations in FHL1, which lead 
to muscle atrophy (  Schessl et al., 2008  ). FHL1 
C132F   and 
FHL1 
H123Y   RBM mutants exhibited reduced NFATc1-mediated 
transcriptional activation, and unlike wild-type FHL1, do not 
induce hypertrophic myotubes. NFATc1 colocalized with mu-
tant FHL1 to reducing body aggregates both in myotubes and 
in muscle from affl  icted RBM individuals. When expressed 
with FHL1-RBM mutants, NFATc1 showed reduced nuclear 
translocation in response to calcineurin activation. These re-
sults suggest that mutant FHL1 contributes to RBM by reduc-
ing NFATc1-dependent transcription of genes that promote 
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software (version 1.34; National Institutes of Health). Alternatively, trans-
verse FDP sections were placed on poly-  L  -lysine  –  precoated glass micro-
scope slides, then air-dried, ﬁ   xed, and stained with hematoxylin and 
eosin, and FDP ﬁ  bers with centralized nuclei within the entire muscle sec-
tion were counted. 
  Transverse human muscle sections were prepared, ﬁ  xed, stained, 
and viewed as described previously (  Schessl et al., 2008  ). Informed con-
sent from human subjects was obtained (Institutional Review Board [IRB] 
approval 2002  –  6-2846 [the Children  ’  s Hospital of Philadelphia, Philadel-
phia, PA] and IRB approvals at the collaborating institutions). 
  Single myoﬁ   brils were isolated from mouse skeletal muscle, then 
ﬁ   xed and stained as described previously (  Knight and Trinick, 1982  ; 
  McGrath et al., 2006  ). Myoﬁ  brils were viewed using a FV1000 laser scan-
ning confocal microscope (Olympus). Widths of 20 myoﬁ  brils per mouse 
were measured using ImageJ software. 
  Muscle ﬁ  ber diameter and area 
  CSA and minimum diameter were analyzed in gastrocnemius and FDP 
mouse skeletal muscle. Transverse 8-  μ  m sections were prepared as de-
scribed previously (  McGrath et al., 2006  ) and viewed using a laser scan-
ning confocal microscope (TCS NT; Leica). CSA (  μ  m 
2  ) and ﬁ  ber diameter 
were calculated (gastrocnemius muscle had   >  500 ﬁ  bers, all ﬁ  bers in the 
FDP) from four to ﬁ  ve mice per genotype for wild-type or FHL1 transgenic 
mice using the analySIS program (Olympus). Alternatively, ﬁ  ber diameters 
were obtained from digital camera images of stained sections using the 
Image-Pro software (Media Cybernetics). Fiber diameter was determined 
by measuring the shortest axis for all ﬁ  bers within a section to the nearest 
10   μ  m, as described previously (  Corbett et al., 2001  ). 
  Fiber type analysis 
  Transverse FDP mouse skeletal muscle sections were prepared, ﬁ  xed, and 
stained for MHC isoforms, as described previously (  Corbett et al., 2001  ; 
  Nair-Shalliker et al., 2004  ). Sections were viewed using a microscope 
(BX50; Olympus) and captured using a Spot camera (V1.4.0) and Spot 
software (Diagnostic Instruments, Inc.). Images were collaged together 
using Photoshop (Adobe). The percentage of type 1, 2A, 2X, and 2B ﬁ  bers 
were calculated in three to ﬁ  ve wild-type and FHL1 transgenic mice. 
  Strength and fatigability test 
  The whole animal strength and fatigability test was performed on 12-wk- 
and 12-mo-old mice as described previously (  Corbett et al., 2001  ;   Joya 
et al., 2004  ). 
  Muscle contractile properties 
  EDL and soleus muscles were dissected tendon-to-tendon from anaesthe-
tized mice (100 mg/kg BW ketamine and 10 mg/kg BW xylazine) for in vitro 
contractile measurements. Optimal muscle length (L  o  ) and maximum isomet-
ric tetanic force (P  o  ) were determined as described previously (  Gregorevic 
et al., 2004  ). Stimulus conditions, lever arm control, and contractile data 
analysis were performed with DMC/DMA computer software (Aurora 
Scientiﬁ  c Inc.). Muscle fatigability was assessed and muscle CSA was de-
termined as described previously (  Gregorevic et al., 2004  ). 
  Growth, transient transfection, and immunoﬂ  uorescence of C2C12 cells 
  C2C12 myoblasts were grown, transiently transfected with Lipofectamine 
2000, and differentiated when indicated. Cells were then ﬁ  xed, permeabi-
lized, blocked, and stained with appropriate nuclear stains and/or anti-
bodies, as described previously (  McGrath et al., 2003  ,   2006  ;   Cottle 
et al., 2007  ). When required, ionomycin diluted in DMSO was added to 
each well after 72 h in differentiation media, at a ﬁ  nal concentration of 
0.5   μ  M for 30 min. C2C12 cells were then immediately ﬁ  xed and stained 
as described at the beginning of this paragraph. When required, 5   μ  M of 
CsA was added to C2C12 cells before and continuously during differentia-
tion, as described previously (  Musar  ò   et al., 1999  ). To measure the myo-
tube diameter, C2C12 cells were transfected as indicated and differentiated 
for 72 h. The maximum myotube diameter was measured in a total of 
  >  300 myotubes transfected with pCGN-FHL1 constructs from three experi-
ments using ImageJ image analysis software (version 1.34). 
  For menadione-NBT staining, after immunoﬂ  uorescence  staining, 
cells were washed thoroughly with PBS, rinsed brieﬂ  y with distilled H  2  O 
(dH  2  O), and stained with menadione-NBT (0.39 mg/ml menadione and 
1 mg/ml NBT in gomori-Tris-HCl buffer, pH 7.4; Sigma-Aldrich) for 20 min 
at room temperature. Cells were washed with dH  2  O and destained by brief 
washes in acetone (30%, 60%, 90%, 60%, and 30%) and rinsed again 
dH  2  O. Samples were viewed using an AX70 microscope ﬁ  tted with an 
Research, Melbourne, Australia). The   pGL2-IL-2   promoter  –  luciferase reporter 
(plasmid 10959; Addgene;   Ichida and Finkel, 2001  ) and pHRLTK (renilla lu-
ciferase; Promega) were purchased. To generate pCGN-FHL1-C132F and 
H123Y, the HindIII to Pst1 fragment of wild-type FHL1 cDNA was excised from 
pCGN-FHL1 and exchanged for HindIII  –  Pst1 fragments containing C132F or 
H123Y mutations (  Schessl et al., 2008  ). The pcDNA3.1 vector (HSA pro-
moter) has been described previously (  Corbett et al., 2001  ). 
  Reagents 
  Reagents were obtained as follows: C2C12 myoblasts (American Type 
Culture Collection); Optimem (Invitrogen); Lipofectamine 2000 (Invitrogen); 
ﬁ   bronectin (Sigma-Aldrich); CsA, propidium iodide, and ﬁ   bronectin 
(Sigma-Aldrich); glutathione  –  Sepharose 4B (GE Healthcare); dual-lucifer-
ase reporter assay system (Promega); and To-Pro-3 and the Quant-iT 
dsDNA assay kit (Invitrogen). 
  Antibodies 
  Primary antibodies used were: mouse anti-HA (Covance),     -tubulin (Invit-
rogen), pan-actin Ab-5 (Thermo Fischer Scientiﬁ   c), poly-histidine clone 
HIS-1, vinculin (Sigma-Aldrich), Pax-7 (R  &  D Systems),     -actinin (Sigma-
Aldrich), rabbit anti-FHL1(  McGrath et al., 2006  ), GATA-2 (H-116), 
NFATc1 (H-110; Santa Cruz Biotechnology, Inc.), myc (Cell Signaling 
Technology), c-myc (Bethyl Laboratories, Inc.), dystrophin (Abcam), goat 
anti-actin, MyoD (M318), Myf5 (C20), myogenin (F50 and M225; Santa 
Cruz Biotechnology, Inc.), GST (Amersham Biosciences), SC-71 (type 2A 
MHC), BF-F3 (type 2B MHC), BAF8 (type 1 MHC), and BF-35 (type 1, 
2A, 2B MHCs) hybridomas (German Collection of Microorganisms and 
Cell Cultures). 6H1 (type 2X MHC) hybridoma supernatant was a gift 
from J. Hoh (University of Sydney, Sydney, Australia;   Lucas et al., 2000  ). 
The sarcomeric MHC antibody (MF20) was obtained from the Develop-
mental Studies Hybridoma Bank, developed under the auspices of the 
National Institutes of Health and maintained by the Department of Bio-
logical Sciences, University of Iowa (  Bader et al., 1982  ). Secondary anti-
bodies were as follows: anti  –  mouse,   –  rabbit, or   –  goat conjugated with 
HRP were obtained from Chemicon; FITC-conjugated anti  –  rabbit IgG was 
obtained from Chemicon; and all Alexa-conjugated secondary antibod-
ies were from Invitrogen. 
  Generation of FHL1 transgenic mice 
  HA-tagged FHL1 (pCGN vector) was PCR ampliﬁ  ed with ﬂ  anking EcoRI 
sites and cloned into the pcDNA3.1+ vector containing an upstream HSA 
promoter (  Brennan and Hardeman, 1993  ). The ﬁ  nal 3.6-kb construct 
(  Fig. 1 A  ) was excised by Nhe1  –  Nae1 digestion, puriﬁ   ed, and micro-
injected into one-cell embryos, then implanted into pseudo-pregnant FVB/n 
mice. Positive founders were bred to FVB/n wild-type mice, and transgenic 
mice were selected by PCR analysis (Table S2). Animals were housed in a 
temperature-controlled room (19  –  22  °  C) with a 12:12-h light/dark cycle. 
Unless otherwise stated, all experiments were performed using 6- or 12-wk-old 
female transgenic mice and wild-type, sex-matched littermate controls, as 
indicated. Mice were humanely killed by CO  2   inhalation followed by 
cervical dislocation, according to the National Health and Medical 
Research Council guidelines (Monash University Animal Ethics no. 
BAM/2001/22). 
  Preparation of muscle lysates 
  The mouse gastrocnemius was dissected, minced, and homogenized on 
ice for 3   ×   30 s (DIAX 900; Heidolph) in 10 times the weight/volume of 
1% NP-40 Tris-Cl buffer, pH 8, then extracted for 1 h at 4  °  C. Lysates were 
centrifuged at 1,000   g   for 30 s, and the total cell lysate obtained was 
stored at     80  °  C. Protein concentration was determined using a DC pro-
tein assay kit (Bio-Rad Laboratories). 20  –  100   μ  g of lysate was analyzed by 
SDS-PAGE and Western blotting. 
  Histological and immunoﬂ  uorescence analysis of skeletal muscle 
  Longitudinal and transverse cryosections of gastrocnemius, EDL, soleus, 
and FDP mouse skeletal muscles were prepared, ﬁ  xed, stained, viewed, 
and deconvolved where appropriate, as described previously (  McGrath 
et al., 2006  ). To obtain polarized light microscopy images, ﬁ  xed longitu-
dinal sections from 12-wk-old male mice were viewed with a microscope 
(AX70; Olympus). When nuclear staining was required, sections were 
pretreated with 200   μ  g/ml RNase A (Sigma-Aldrich), and nuclei were de-
tected by costaining with To-Pro-3 iodide (Invitrogen) or Dapi (Sigma-
Aldrich) for 10 min. The total number of gastrocnemius muscle ﬁ  bers with 
centralized nuclei or Pax-7  –  positive nuclei were counted in   >  500 ﬁ  bers in 
at least three wild-type and transgenic mice using ImageJ image analysis JCB • VOLUME 183 • NUMBER 6 • 2008  1046
  Image and statistical analysis 
  All microscopy was performed at Monash Microimaging at Monash Uni-
versity, Australia. All samples for microscopy were mounted in SlowFade 
reagent (Invitrogen) and viewed at room temperature. Confocal micros-
copy was performed using a confocal laser scanning microscope (TCS/
NT; Leica) on a DMRBE upright microscope. Leica Confocal Software (LCS 
version 2.5; Leica) was used for confocal image acquisition. Fluorescence 
and light microscopy was performed using a microscope (AX70 Provis; 
Olympus) ﬁ  tted with either a charge-coupled device (color; DP70; Olym-
pus) or FVII monochrome (black and white; Olympus) camera. AnalySiS 
software was used for image capture and analysis. 
  Western blot ﬁ  lms were scanned and band signal intensities were 
determined using a Gel-Pro Analyzer (version 3.1; Media Cybernetics). 
Densitometry values were expressed as a fold difference relative to the 
control, standardized to corresponding total actin/    -tubulin values. All re-
sults are presented as the mean   ±   SE (SEM). Statistical analysis was per-
formed using the unpaired student  ’  s   t   test unless stated otherwise. p-values 
of   <  0.05 were considered signiﬁ  cant. 
  Online supplemental material 
  Fig. S1 shows the normal morphology of the sarcomere and the increased 
myoﬁ  bril width in FHL1 transgenic mice. Fig. S2 shows hypertrophy of type 
2B ﬁ  bers of the EDL in FHL1 transgenic mice. Fig. S3 shows knockdown 
of endogenous FHL1 in C2C12 cells using FHL1 siRNA oligonucleotides. 
Table S1 shows the contractile data from EDL muscles of FHL1 transgenic 
and wild-type mice. Table S2 shows the sequences of all oligonucle-
otides used. Online supplemental material is available at http://www.jcb
.org/cgi/content/full/jcb.200804077/DC1. 
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F-view II FW camera (Olympus). Images were taken using the analysis FIVE 
program (Olympus). 
  C2C12 differentiation 
  C2C12 myoblasts stably transfected with HA-    gal or HA-FHL1 have been 
described previously (  McGrath et al., 2006  ). All experiments analyzing the 
differentiation of C2C12 myoblasts were performed as described previously 
(  Cottle et al., 2007  ). In brief, 10 
5   stably transfected myoblasts were plated 
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(B) the differentiation index (proportion of nuclei localized within MHC-positive 
myotubes), and (C) the fusion index (mean number of nuclei per MHC-
positive myotube;   Sabourin et al., 1999  ). Each experiment was performed 
in triplicate, and for all cell counts, a minimum of four random ﬁ  elds were 
scanned for each slide to ensure that   ≥  100 cells were scored for each repli-
cate. Cells counts were quantiﬁ   ed using ImageJ software (version 1.34; 
  Abramoff et al., 2004  ). For Western blot analyses, Triton X-100  –  soluble 
lysates were prepared, protein concentration was measured using a D  C   
protein assay reagent (Bio-Rad Laboratories), and 25-  μ  g lysates were 
immuno    blotted with MyoD (1:100), Myf5 (1:100), myogenin (F50; 1:500), 
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  Protein/DNA ratio 
  The method for measurement of the protein/DNA ratio of C2C12 myo-
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pGEX-5   ×   1-GATA-2 together with pET-30a(+)(His-tag) or pET-30a(+)-
NFATc1. Recombinant protein production was induced, and direct protein 
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(  Cottle et al., 2007  ). 
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